Review

ROR: Nuclear Receptor for Melatonin or Not?

Haozhen Ma 1,2, Jun Kang 1,2, Wenguo Fan 1,2, Hongwen He 2,3,* and Fang Huang 1,2,*

1 Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou 510055, China; mahzh5@mail2.sysu.edu.cn (H.M.); kangj5@mail2.sysu.edu.cn (J.K.);
fanweng@mail.sysu.edu.cn (W.F.)
2 Guangdong Provincial Key Laboratory of Stomatology, Guangzhou 510080, China
3 Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou 510080, China
* Correspondence: hehw@mail.sysu.edu.cn (H.H.); hfang@mail.sysu.edu.cn (F.H.);
Tel.: +86-20-8733-0570 (H.H. & F.H.)

Abstract: Whether the retinoic acid-related orphan receptor (ROR) is a nuclear receptor of melatonin remains controversial. ROR is inextricably linked to melatonin in terms of its expression, function, and mechanism of action. Additionally, studies have illustrated that melatonin functions analogous to ROR ligands, thereby modulating the transcriptional activity of ROR. However, studies supporting these interactions have since been withdrawn. Furthermore, recent crystallographic evidence does not support the view that ROR is a nuclear receptor of melatonin. Some other studies have proposed that melatonin indirectly regulates ROR activity rather than directly binding to ROR. This review aims to delve into the complex relationship of the ROR receptor with melatonin in terms of its structure, expression, function, and mechanism. Thus, we provide the latest evidence and views on direct binding as well as indirect regulation of ROR by melatonin, dissecting both viewpoints in-depth to provide a more comprehensive perspective on this issue.

Keywords: retinoic acid-related orphan receptor; melatonin; nuclear receptor; ligand

1. Introduction

Nuclear receptors with typical domain structures and conserved sequences, such as thyroid hormone and sterol receptors, are a superfamily of ligand-dependent transcription factors [1,2]. In the 1980s, as new members of this superfamily were being explored, a number of orphan receptors with unknown ligands were identified, including retinoic acid-related orphan receptor (ROR) [3].

As a ligand-dependent transcription factor, ROR modulates the transcription of target genes by binding to ROR response elements (RORE) present in the target genes. ROR is implicated in modulating a variety of physiological processes, including cerebellar development, lymphoid tissue development, retinal development, bone formation, lipid metabolism, circadian rhythm, oxidative stress, and inflammation suppression. Furthermore, ROR is also a promising therapeutic target for autoimmune diseases, tumours, obesity, diabetes, and other diseases. Thus, the identification of novel natural and synthetic ROR ligands is a research hotspot, and further studies are required to facilitate the establishment of targeted therapies for the aforementioned physiological processes and diseases [4].

Melatonin (N-acetyl-5-methoxytryptamine) is an evolutionary molecule found in bacteria, fungi, algae, plants, invertebrates, and vertebrates. It regulates multiple functions that have developed along the evolutionary timescale. In humans, melatonin is pleiotropic [5]. Melatonin modulates sleep-wake rhythms, reproduction, and bone metabolism; it also affects the immune, neurological, cardiovascular, digestive, urinary, and endocrine systems. Moreover, it exhibits anti-inflammatory, antioxidant, anti-infective, and anti-tumour properties while also being a potential therapeutic agent for obesity, cardiovascular diseases, and neurodegenerative disorders. The functions of melatonin are often mediated through...
its binding to either type 1 or type 2 melatonin membrane-bound receptors (MT1/MT2) [6]. Activation of these different membrane receptors may lead to opposing outcomes. For instance, the MT1-mediated vasoconstrictive effects of melatonin are in contrast to the MT2-mediated vasodilatory effects [7]. Melatonin also functions through non-receptor-mediated mechanisms, such as its powerful free radical scavenging capability [6].

Melatonin is speculated to have nuclear binding sites, in addition to its membrane-bound receptors. In the 1990s, studies reported melatonin binding sites in purified cell nuclei derived from rat organs, including the liver, spleen, and thymus [8,9]. Contemporaneous studies illustrated that melatonin bound and activated the nuclear receptors RORα and RORβ, bringing the claim that ROR was the nuclear receptor of melatonin to a culmination [10,11]. This claim was partially corroborated by subsequent studies where several functions of melatonin were determined to be mediated by ROR. Furthermore, melatonin was found to play a ROR-ligand-like role [12,13]. Another study reported the co-localization and co-immunoprecipitation of melatonin and ROR, confirming their interaction [14]. However, this claim has faced scepticism and the study asserting that the direct binding between retinoid Z receptors β (RZRβ, now known as RORβ) and melatonin was retracted as it could not be reproduced [10]. Since then, several studies have demonstrated that melatonin indirectly regulates the transcriptional activity of ROR through intermediate steps [15,16]. Crystallographic evidence suggests that melatonin and its metabolites are not high-affinity ligands for ROR [17]. Therefore, a debate is ongoing on whether ROR is a nuclear receptor of melatonin.

This review discusses the complex relationships of ROR with melatonin in terms of ROR’s structure, expression, function, and mechanism. We provide the latest evidence on both direct binding or indirect regulation of ROR by melatonin, and dissect both aspects in-depth in an attempt to provide a more comprehensive perspective on this issue.

2. Expression and Functions of Retinoic Acid-Related Orphan Receptor

2.1. Basic Information of Retinoic Acid-Related Orphan Receptor

In 1993, melatonin was detected in the nuclei of cells, which led to the inference of the presence of melatonin’s nuclear receptors [9,18,19]. Subsequently, it was proposed that the ROR family comprised the nuclear receptors for melatonin, with RORα1 and RORα2 (splicing variants of RORα), RZRβ (now known as RORβ) [10], and RORγ being the main binding sites.

The ROR group includes three members: RORα (RORA, NR1F1, or RZRα), RORβ (RORB, NR1F2, or RZRβ), and RORγ (RORC or NR1F3) [20]. Four RORα isoforms (RORα1–4) have been identified in humans, whereas only two have been reported in mice (RORα1 and RORα4). Murine expression of the RORβ1 and RORβ2 isoforms have been reported, but only the RORβ1 isoform has also been identified in humans. Both humans and mice express RORγ1 and RORγ2 (RORγ2 is also known as RORγt).

The expression patterns for the three members of the ROR group varies, and some isoforms appear to be tissue-specific. RORα is expressed in a broad range of tissues and organs, including the skin, adipose tissue, skeletal muscles, cerebellum, liver, kidneys, and thymus. In mice, high expression levels of RORα1 and RORα4 are reported in the cerebellum; however, in other tissues, RORα4 is the predominantly expressed form. Human RORα3, thus far, has been detected only in the testes. RORβ expression is restricted to the central nervous system, where it plays a role in sensory and circadian rhythms, as well as functions within the spinal cord and sensory organs [21]. RORβ1 has been detected in the cerebral cortex, pituitary gland, spinal cord, cochlea, and retina, while RORβ2 has been identified only in the rod photoreceptors and the pineal gland [22,23]. RORγ1 expression is prevalent in the muscles, adipose tissue, liver, and kidneys, similar to RORα [24]. However, RORγt, also known as the thymic isoform, is confined to certain immune cells, such as group 3 innate lymphoid cells (ILC3) [25] and T helper 17 (Th17) cells [26].
2.2. Functions of Retinoic Acid-Related Orphan Receptor: Related to or Independent of Melatonin

The RORs mainly regulate physiological and pathological processes, including immunity, development (especially the nervous system), circadian rhythm, tumours, cellular metabolism, and oxidative stress, which is also the main functional areas of melatonin. Moreover, various studies have reported that RORs mediate functions of melatonin [27–30] and that melatonin can regulate the transcriptional activity of RORs, boosting the transcription of ROR target genes [12–14]. However, RORs have also been found to function independently of melatonin-induced signalling [21,31–34].

RORα is intimately linked to the melatonin function and is extensively involved in the pleiotropic effects of melatonin [27–30,35–40]. The melatonin-RORα axis plays a role in immune, reproductive, and cardiovascular systems, as well as a variety of physiological and pathological processes such as oxidative stress, circadian rhythms, development, and oncogenesis. In the immune system, the melatonin-RORα pathway is crucial for the induction of T cell differentiation, downregulation of autoimmune responses, and anti-inflammatory functions. García et al. demonstrated that melatonin relies on RORα to suppress nuclear factor kappa-B (NF-κB)-related inflammatory responses; moreover, it promoted antioxidant defence during sepsis treatment [30]. Multiple sclerosis progression is tamed by restraining Th17 cell differentiation and stimulating type 1 regulatory T (Treg) cell differentiation via the melatonin-RORα axis [28]. In systemic lupus erythematosus, another autoimmune disease, melatonin protects endothelial cells via a RORα-dependent mechanism by reducing the expression of inflammatory factors and inhibiting macrophage migration [29]. Melatonin protects vessels from rupture of hyperlipidaemia-induced arterial plaques via RORα-regulated macrophage polarisation [27]. Regarding the reproductive system, the melatonin-RORα pathway inhibits apoptosis of Leydig cells (testicular mesenchymal stromal cells) and promotes testosterone secretion [35,41]. In addition, melatonin ameliorates oxidative stress during cardiac hypertrophy and cardio/cerebral ischemia-reperfusion in a RORα-dependent manner, with beneficial effects on pathological cardiac hypertrophy, myocardial infarction, ischemic stroke, and diabetic cardiomyopathy [12,36–38]. For cancer suppression, RORα, as a circadian rhythm-related gene, contributes to melatonin-induced suppression of liver and colorectal cancers [42,43]. In addition, melatonin inhibits the activation of hepatic stellate cells through RORα-mediated suppression of 5-lipoxygenase [44]. RORα also mediates the role of melatonin in regulating hair growth and reducing neuropathic pain [45–47]. Both melatonin and RORα are associated with the regulation of bone and lipid metabolism, insulin secretion, and glucose tolerance; however, it is difficult to determine whether their effects are related [5,48,49].

However, several functions of RORα are irrelevant to melatonin signalling. For example, RORα is critical for the development of cerebellar Purkinje cells. As a result, mice lacking RORα show cerebellar atrophy and ataxia [31]. However, no implication of melatonin in cerebellar development has been reported.

RORβ and its functions are less relevant to melatonin signalling. RORβ is overexpressed at sites that regulate circadian rhythms, including the suprachiasmatic nuclei (SCN) and pineal gland. Fluctuations in the mRNA levels of RORβ in the pineal gland are similar to that of melatonin synthesis. However, Masana et al. showed that RORβ did not participate in melatonin-mediated circadian rhythm and phase shifting, despite the rhythmic nature of its expression [50]. Moreover, RORβ plays a vital role in retinal formation and function; it promotes the proliferation of retinal progenitor cells while also acting as a key transcription factor for modulating the differentiation of rod photoreceptors, amacrine cells, and horizontal cells [23,51]. Rods are photoreceptor cell that senses low light stimuli and are sensitive to light intensity. Amacrine and horizontal cells are responsible for the integration of visual signals. Furthermore, RORβ plays a crucial role in perceptual and cognitive functions by facilitating the formation of layered structures in the cerebral cortex, which are derived from the migration and differentiation of neurons. RORβ reportedly acts as a marker for neurons in layers IV and V of the cerebral cortex, as well as in the barrel cortex [21,32]. Mutations in the human RORβ gene contribute to
epilepsy and intellectual deficiencies [33,34]. The absence of RORβ in mice also results in gait abnormalities and the suppression of reproductive functions [21]. However, no studies have reported the aforementioned functions for melatonin. Interestingly, recent in vitro and in vivo data has revealed that knocking down or genetically deleting RORβ boosts osteogenesis and restrains bone resorption; therefore, this could be applied as a new target for the treatment of osteoporosis [52,53]. Coincidentally, melatonin reportedly promotes osteogenic differentiation; thus, it can also be used to treat osteoporosis [54].

RORγ mediates several processes regulated by melatonin, with major reports indicating its involvement in the immune system and tumour suppression. Impaired thymopoiesis, deficiency of Peyer’s patches and peripheral lymph nodes, and a high incidence of thymic lymphoma have been reported in RORγ−/− mice [55,56]. Furthermore, RORγ has been identified as a key modulator of the differentiation and development of Th17 cells, ILC3 cells, and γδ T cells [25,57,58]. Moreover, by regulating these cells, RORγ has emerged as a potential therapeutic target for autoimmune diseases such as multiple sclerosis, asthma, lupus, atopic dermatitis, inflammatory bowel disease, arthritis, and psoriasis [59,60]. More importantly, melatonin can regulate the immune system via RORγ. Farez et al. demonstrated that melatonin contributes to the amelioration of autoimmune diseases, such as multiple sclerosis, by both suppressing the differentiation of pathogenic Th17 cells via RORγ, and promoting the development of protective Tr1 via RORα [61]. Xiong et al. revealed that the melatonin-RORα/γ pathway mediates the green light-induced proliferation of chicken T lymphocytes [62]. In addition to the immune system, the melatonin-RORγ axis also suppresses cancer [39]. In vitro and in vivo studies have shown that melatonin may induce growth and angiogenesis suppression in gastric cancer cells by downregulating RORγ expression [39]. RORγ has also been suggested as a possible emerging target for the treatment of obesity-related insulin resistance. Under high-fat diet conditions, RORγ−/− mice exhibit less fat accumulation and reduced insulin resistance [40]. Coincidentally, melatonin can also induce preadipocyte apoptosis, diminish visceral fat, and ameliorate insulin resistance [63,64]. Although both melatonin and RORγ are recognised as potential therapeutic agents for obesity and diabetes, the role of the melatonin-RORγ axis in adiposity and glucose metabolism has not yet been reported.

3. Mechanism of Action of Retinoic Acid-Related Orphan Receptor

3.1. Gene Transcription Modulation

With highly conserved sequences, the ROR genes encode proteins spanning 459–556 amino acids. Similar to other nuclear receptors, ROR has a classical structure consisting of four functional domains, including an amino-terminal (A/B) domain, a conserved DNA-binding domain (DBD) with two zinc fingers, a ligand-binding domain (LBD) located at the carboxyl terminus, and a hinge [65]. The transcription factor ROR modulates target gene transcription by binding to RORE in the target gene (Figure 1). DBD identifies RORE, which is composed of the AGGTCA core motif and subsequent A/T-rich sequences. Specifically, the interaction between ROR and RORE is accomplished by identifying the core motif in the main groove by p-box, which is the ring between the last two cysteines in the first zinc finger. Furthermore, the C-terminal extension, a region downstream of the two zinc fingers that can identify the 5′-AT-rich RORE segment in the small adjoining groove, also contribute to the binding of ROR to RORE [66]. The multifunctional LBD mediates ligand binding, co-activator or co-repressor recruitment, and nuclear localisation [66]. Ligands binding triggers conformational alterations of the LBD, with the subsequent recruitment of co-activators or co-repressors, ultimately boosting or repressing the target gene transcription. Recruitment of co-activators induces chromatin remodelling through histone acetylase, which results in increased gene expression [67]. In contrast, co-repressors induce chromatin compaction via histone deacetylase, thereby inducing the repression of gene expression. The co-activators recruited by ROR receptors include NCOA1, NCOA2, NCOA3, NCOA6, HTATIP, PPARGC1A(PGC-1α), and CTNNB1 (β-catenin), while co-repressors include NCOR1, NCOR2, NRIP1 (RIP140), NIX1, and HR (Hairless) [68–70].
Figure 1. The mechanism of transcriptional modulation mechanism by ROR and REV-ERB. ROR and REV-ERB are ligand-dependent transcription factors. Ligand binding triggers conformational alterations in both ROR or REV-ERB. As a result, they recruit co-activators or co-repressors to ultimately boost or repress target gene transcription. REV-ERB and ROR are often co-expressed, and both specifically recognise RORE. Consequently, ROR and REV-ERB competitively bind to RORE present in the regulatory region of target genes, forming a mutually antagonistic relationship. In most cases, ROR recruits co-activators and promotes gene transcription, whereas REV-ERB recruits co-repressors and inhibits gene transcription.

In addition to the cofactors, the crosstalk of nuclear receptors and the post-translational modifications of ROR also participate in modulating ROR activity. The competitive binding to RORE by ROR and REV-ERB is a typical example of crosstalk between nuclear receptors (Figure 1). ROR and REV-ERB are ligand-dependent transcription factors. Ligand binding triggers conformational alterations in both ROR or REV-ERB. As a result, they recruit co-activators or co-repressors to ultimately boost or repress target gene transcription. REV-ERB and ROR are often co-expressed, and both specifically recognise RORE. Consequently, ROR and REV-ERB competitively bind to RORE present in the regulatory region of target genes, forming a mutually antagonistic relationship. In most cases, ROR recruits co-activators and promotes gene transcription, whereas REV-ERB recruits co-repressors and inhibits gene transcription. For instance, brain and muscle Arnt-like-1 (BMAL1) is a key molecule regulating the biological clock. Here, ROR and REV-ERB, which are expressed in an opposing circadian oscillatory manner, dynamically regulate the expression of the target gene BMAL1 by competitively binding to the RORE of BMAL1, thereby inducing contrasting effects. Through this regulation, the expression levels of BMAL1 also undergo circadian oscillations, which are vital for the proper functioning of circadian rhythms [71] (Figure 1). Ubiquitination and SUMOylation also modulate the transcriptional activity of ROR. As mentioned previously, RORγ alters IL-17 expression and consequently influences the development of inflammatory diseases. Recent reports indicate that the ubiquitination and SUMOylation of RORγ suppress RORγ, which subsequently represses colonic inflammation [72,73].

3.2. Ligands

ROR is dependent on ligands for transcriptional modulation. Such ligands are categorised by their impact on receptor transcriptional activity, comprising agonists, antagonists, and inverse agonists. Agonist binding induces increased co-activator recruitment and enhances the transcription of target genes. Antagonists have no influence on the transcriptional activity of the receptor but block agonist-mediated activation. However, inverse agonists recruit extra co-blockers to downregulate the basal activity of the recep-
tor [4] (Figure 2). The mechanism underlying inverse agonists remains unclear and may be attributed to the hindered binding of the co-activators [74].

![Figure 2. Graphical illustration of the impact of agonists, antagonists, and inverse agonists on the co-activator recruitment and downstream transcription of ROR. Agonist binding induces increased co-activator recruitment and enhances the transcription of target genes. Antagonists have no influence on the transcriptional activity of the receptor but block agonist-mediated activation. However, inverse agonists recruit extra co-blockers to downregulate the basal activity of the receptor.](image)

The ROR family acts as a vital regulator of circadian rhythm, immunity, development, oxidative stress, and cellular metabolism. Novel ligands of ROR have been enthusiastically identified and synthesised to establish positive modulators and therapeutics. For example, the novel endogenous ligand of RORα, maresin 1, has been identified as a therapeutic agent for non-alcoholic steatohepatitis by activating RORα to regulate hepatic macrophage polarity [75]. In addition, SR1001, a high-affinity ligand for RORα and RORγ, was synthesised to effectively alleviate autoimmune diseases and type 1 diabetes by targeting RORα and RORγ to restrain the function of Th17 cells [76,77]. New putative ligands for ROR have been identified using strategies such as the AlphaScreen assay, differential scanning fluorimetry, virtual screening, and cell-based reporter assays. Table 1 illustrates the natural and synthetic ligands of ROR as well as their applications.

**Table 1. Ligands of retinoic acid-related orphan receptor.**

| Name            | Type              | Effect         | Origin                        | Applications                                                |
|-----------------|-------------------|----------------|-------------------------------|------------------------------------------------------------|
| **Natural Ligands** |                   |                |                               |                                                            |
| Cholesterol     | RORα agonist      | EC_{50}: 200 nM | X-ray crystallography         | Suppressing inflammation and dyslipidemia [78].            |
| Cholesterol Sulfate | RORα agonist    | X-ray crystallography | Regulating anticancer immunity [79] and ameliorating rheumatoid arthritis [80]. |
| Stearic acid    | RORβ antagonist   | X-ray crystallography | Unclear                      |                                                            |
| All-trans retinoic acid | RORβ antagonist | IC_{50} = 0.15 nM | X-ray crystallography         | Unclear                                                    |
## Table 1. Cont.

| Name | Type | Effect | Origin | Applications |
|------|------|--------|--------|--------------|
| **Natural Ligands** | | | | |
| **Digoxin** | RORγ inverse agonist (at high concentrations); RORγ agonist (at low concentrations) | IC₅₀: 1.98 µM; EC₅₀: unclear | Chemical screen | A therapeutic agent against Th17-mediated inflammation and autoimmune diseases, including encephalomyelitis [81], neovascular retinopathy [82], atherosclerosis [83] and autoimmune arthritis [84]; Inducing RORγ-dependent transcription in HepG2 and Th17 cells [85]. |
| **Ursolic Acid** | RORγ inverse agonist | IC₅₀: 680 nM | Chemical screen and luciferase reporter assays | A therapeutic agent against IL-17-mediated inflammation and autoimmune diseases [86]. |
| **7α-hydroxy-cholesterol and 7-ketocholesterol** | RORα/γ Inverse agonist | IC₅₀: 1.3 µM (RORα); 0.62–2.2 µM (RORγ) | Chromatin immunoprecipitation | Unclear [87]. |
| **20α-hydroxycholesterol, 22R hydroxycholesterol and 25-hydroxycholesterol** | RORγ agonist | EC₅₀: 20–40 nM | Alphascreen | Unclear [88]. |
| **Synthetic Ligands** | | | | |
| **ALTA 1550** | RORβ antagonist | IC₅₀ = 0.039 nM | Crystallography | Unclear |
| **T0901317** | RORα/γ inverse agonist | IC₅₀: 2.0 µM (RORα); 1.7 µM (RORγ) | AlphaScreen | Unclear [89]. |
| **SR1001** | RORα/γ inverse agonist | IC₅₀: 172 nM (RORα); 117 nM (RORγ) | Luciferase reporter assays | A therapeutic agent against Th17-mediated diseases, including multiple sclerosis [76], type 1 diabetes [77], atopic dermatitis, and acute dermatitis [90]. |
| **SR1078** | RORα/γ agonist | Unclear | Luciferase reporter assays | Regulating CD8⁺ T cell-mediated immune response [91], therapeutic strategy for rheumatoid arthritis [80] and acute kidney injury [92]. |
| **SR3335** | RORα inverse agonist | IC₅₀: 220 nM | Luciferase reporter assays | Slimming effect [93], suppression on elevated hepatic glucose production in type 2 diabetics [94], mitigation of sepsis stemming from *Enterococcus faecalis* oral infection [95]. |
| **SR2211** | RORγ inverse agonist | IC₅₀: 105 nM | Luciferase reporter assays | A therapeutic agent against Th17-mediated diseases [96] and doxorubicin resistance in prostate cancer [97]. |
| **SR1555** | RORγ inverse agonist | IC₅₀: 1.5 µM | Luciferase reporter assays | Anti-obesity [98] and therapeutic effects against Th17-mediated autoimmune diseases. |

1 EC₅₀: concentration for 50% of maximal effect. 2 IC₅₀: half-maximal inhibitory concentration.

Regarding melatonin, luciferase reporter gene assays have confirmed that melatonin increases the transcriptional activity of RORα [13,61]. Co-localization and co-immunoprecipitation of melatonin and RORα were reported by Lardone et al. [14], illustrating the interaction between melatonin and RORα.
3.3. Related Pathways

Melatonin and ROR are dependent on similar signalling pathways. ROR is a crucial regulator of inflammation and immunity and always acts via the NF-κB pathway. For example, RORα suppresses LPS-induced inflammation triggered by the SIRT1-NF-κB pathway [99]. Through extracellular signal-regulated kinase (ERK) and the NF-κB pathway, ROR ameliorates brain inflammation [100]. Moreover, the NF-κB pathway also mediates the protective effects of the melatonin-RORα axis against ischemia-reperfusion [36]. In addition to the NF-κB signalling pathway, the AMP-activated protein kinase α-signalling trans-ducer and activator of transcription (AMPKα-STAT) and the IL-6-STAT3 pathways also mediate the anti-inflammatory effect of ROR [27,101]. Recently, Han et al. identified a novel pathway, known as the MaR1/RORα/12-LOX loop, which plays a potential therapeutic role in non-alcoholic steatohepatitis [75].

Melatonin also modulates inflammation via the NF-κB pathway [102]. Additionally, the p38 mitogen-activated protein kinase (MAPK) pathway, transforming growth factor-β1 (TGF-β1)/Smad3 pathway, Toll-like receptor 4 (TLR4)/MyD88/NF-κB pathway, and Janus kinase 2 (JAK2)-STAT3 pathway also mediate the effects of melatonin on the immune system. For instance, melatonin influences T/B cell activation and adjusts immune homeostasis via the p38 MAPK and NF-κB pathways [103]. Melatonin has also been used for the treatment of LPS-induced testicular inflammation in sheep by repressing the p38 MAPK pathway [104]. Furthermore, it reportedly relies on the STAT3 pathway to attenuate cancers associated with inflammation [105]. In addition, melatonin ameliorates renal inflammation by targeting the TGF-β1/Smad3 signalling pathway [106]. In mice, melatonin inhibits microglial inflammation and improves cognitive impairment by downregulating the TLR4/MyD88/NF-κB signalling pathway [102]. Melatonin treatment also reduces myocardial inflammation by targeting the JAK2-STAT3 pathway [107]. Moreover, it also reduces neuroinflammation via the Sirt1/Nrf2/heme oxygenase-1 (HO-1) route [108].

Regarding anticancer effects, ROR is reportedly associated with the Wnt/β-catenin signalling pathway. The ROR-Wnt/β-catenin axis regulates the carcinogenesis and progression of liver, colon, prostate, and colorectal cancers, providing emerging therapeutic targets for these cancers [109–112]. Furthermore, the proliferation of oral squamous cell carcinoma cells can be restrained by inhibiting the RORα-p53 pathway [113]. The anticancer effects of melatonin are mediated not only by the Wnt/β-catenin pathway but also through a complex network of signalling pathways, mainly involving the phosphatidylinositol 3-kinase/AKT/mechanistic target of rapamycin (PI3K/AKT/mTOR), NF-κB, ERK, and cyclooxygenase-2/prostaglandin E2 (COX-2/PGE2) signalling pathways, responsible for the anti-proliferative and pro-apoptotic effects on cancer cells [114,115], and c-Jun N-terminal kinase (JNK), Akt-MAPKs, and NF-κB pathways, responsible for anti-metastatic effects [116,117].

4. Retinoic Acid-Related Orphan Receptor and Melatonin: Direct Binding or Indirect Modulation?

4.1. Retinoic Acid-Related Orphan Receptor and Melatonin: Inextricably Linked

Nuclear receptors for melatonin are thought to exist because of melatonin’s ability to penetrate cells and the detection of melatonin’s nuclear binding site [8]. In 1994, Becker-André et al. revealed that melatonin bound to and activated the nuclear receptor RZRβ (now known as RORβ) [10]. One year later, Wiesenberg et al. reported that melatonin could also bind to and activate RORα; moreover, they identified a novel synthetic ligand of RORα, CGP 52608, which is similar to melatonin in function [11]. Besides, the binding of 2-[125I]iodomelatonin ([125I]melatonin) to purified cell nuclei in the spleen and thymus was demonstrated, and this binding of melatonin could be substituted by CGP 52608. The aforementioned studies implied that the nuclear receptor of melatonin might be ROR. Since this initial discovery, the belief that ROR serves as the nuclear receptor for melatonin has been extensively adopted by many researchers [14,28,38,118,119]. Furthermore, numerous
studies have illustrated that ROR is linked to melatonin in a myriad of direct or indirect ways, supporting the proposition that melatonin is a ROR ligand (Table 2).

Table 2. Findings for or against the hypothesis of melatonin as a ROR ligand.

| Findings | References |
|----------|------------|
| **In Support of Melatonin as a ROR Ligand** | |
| Melatonin binds and activates the nuclear receptor RZβ. | [10] |
| Melatonin binds and activates RORα. | [11] |
| CGP 52608 (a novel synthetic ligand of RORα) is similar to melatonin in function. The binding of 2-[125I]iodomelatonin ([125I]melatonin) to purified cell nuclei in the spleen and thymus was demonstrated, and this binding of melatonin could be substituted by CGP 52608. | [11] |
| Melatonin and ROR have identical functions. | [5,40,48,52,54,63,64] |
| ROR mediates a number of melatonin functions. | [27–30,35–40] |
| Melatonin exerts an additional effect on the transcription of ROR target genes. | [12,30,37,61] |
| Co-localisation and co-immunoprecipitation of melatonin and ROR. | [14] |
| Melatonin functions via ROR without the mediation of membrane receptors. | [120,121] |
| **Refute that Melatonin is a ROR Ligand** | |
| The studies claimed that melatonin bound to RORβ was not reproducible. | [6,10] |
| ROR functions independently of melatonin-induced signalling. | [21,23,31–34,51] |
| Melatonin and its metabolites exhibit no significant impact on the transcriptional activity of RORα and RORγ. | [17] |
| Molecular modelling indicates that melatonin and its metabolites are not high-affinity ROR ligands. | [17] |
| Melatonin directly binds to membrane receptors (MT1 or MT2) and further modulates ROR. | [15,16] |

First, ROR appears to be related to melatonin in its expression pattern. Melatonin, which is secreted by the pineal gland at night, regulates circadian rhythm and the sleep and wake cycle. Coincidentally, some members of ROR are also expressed in the pineal gland and in other key sites that modulate circadian rhythms. In addition, all three members of ROR are expressed in a circadian oscillatory pattern [20]. Moreover, ROR is responsible for modulating circadian rhythms. ROR and REV-ERB form a mutually antagonistic relationship, whereby they competitively bind to RORE in the regulatory region of target genes. ROR promotes target gene transcription, whereas REV-ERB represses it. The expression of ROR and REV-ERB fluctuates circadian rhythmically with opposite trends and dynamically modulates the transcription of the target gene BMAL1. Thus, BMAL1, a key factor in the control of the mammalian circadian biological clock, is also expressed in a circadian pattern, resulting in the effective amplification of the circadian oscillation [71].

Functionally, many studies have suggested that melatonin and ROR have identical functions [5,40,48,52,54,63,64], and that ROR mediates a number of melatonin functions [27–30,35–40]. Moreover, melatonin is found to exert an additional effect on the transcription of target genes of ROR, as reported by studies covering a wide range of areas, including immune regulation, inflammation suppression, oxidative stress, circadian rhythms, tumour development, reproduction, hair growth, bone metabolism, and lipid metabolism. Both melatonin and ROR mediate bone and lipid metabolism. In addition, melatonin often functions through the mediation of ROR. As previously mentioned, the melatonin-ROR axis exerts therapeutic effects on systemic lupus erythematosus, hyperlipidemia, myocar-
dial infarction, and ischemic stroke via suppressing inflammation and reducing oxidative stress. This axis also represses liver, gastric, and colorectal cancers, reduce neuropathic pain, and alleviate liver fibrosis. Furthermore, melatonin also modulates the transcriptional activity of ROR. For example, Garcia et al. revealed that melatonin treatment remarkably elevated RORα expression while suppressing REV-ERB expression, contributing to the transcriptional upregulation of the ROR target gene, BMAL1. The activation of the melatonin-RORα pathway leads to NF-κB inhibition, resulting in an anti-inflammatory effect [30]. Using luciferase reporter gene assays and chromatin immunoprecipitation assays, Farez et al. demonstrated that melatonin promoted binding between ROR and the IL10 RORE, thus activating IL10 expression and boosting regulatory T cell differentiation to alleviate multiple sclerosis [61]. Zhao et al. found that RORα played a regulatory role in diabetic cardiomyopathy and that the addition of melatonin exerted an SR1078-like (RORα agonist) effect, stimulating the transcription of RORα target genes and ameliorating diabetic cardiomyopathy [12]. Xu et al. reported that in the presence of melatonin, RORα expression was upregulated, with a subsequent enhancement of RORα transactivation of manganese-dependent superoxide dismutase to resist pathological myocardial hypertrophy [37]. All this evidence supported that melatonin intensified ROR transcriptional activity and further boosted target gene transcription.

More importantly, some studies have demonstrated that melatonin plays a role comparable to that of a determined ROR ligand. Kim et al. demonstrated that melatonin was characteristically similar to that of cholesterol sulphate (an agonist of RORα) and enhanced the transcriptional activity of the target gene hypoxia-inducible factor 1α [13]. Similarly, Zhao et al. reported that melatonin-induced target gene transcription was comparable to that in response to SR1078 (an agonist of RORα) [12]. Not only did melatonin trigger the transcriptional activation of ROR target genes in a manner that resembled ROR ligands, but it also co-localized and co-immunoprecipitated with ROR. Lardone et al. detected the co-localization of melatonin and ROR in the nucleus of Jurkat T cells, as well as their co-immunoprecipitation [14], providing evidence for the interaction between melatonin and ROR.

Currently, the recognised pathways through which melatonin exerts its biological effects include: (a) G protein-coupled membrane receptors (MT1, MT2) signalling, (b) putative nuclear receptors (RORα, β, γ) signalling, and (c) free radical elimination signalling unrelated to the receptors. In some cases, melatonin functions via ROR and not via free radical removal or by membrane receptors. For example, Huang et al. demonstrated that melatonin suppressed the proliferation of rat dental papilla cells and simultaneously boosted their differentiation, while luzindole (a competitive MT1/MT2 antagonist) failed to reverse the effects of melatonin, indicating that the aforementioned functions of melatonin are independent of membrane receptors [120]. Recently, they further demonstrated that ROR mediated the enhancement of dental papilla cell differentiation by melatonin [121]. It may be a piece of circumstantial evidence in support of ROR as a nuclear receptor of melatonin.

4.2. Retinoic Acid-Related Orphan Receptor and Melatonin: Indirect Modulation

In the late 1990s, the study claiming that melatonin bound to RORβ was withdrawn, as its findings were not reproducible [6,10]. Despite the retraction of the literature, unfortunately, many studies still adopted the theory that ROR served as melatonin’s nuclear receptor to explain the role of melatonin or ROR, and subsequent publications repeated these explanations. With the emergence of new evidence from crystallographic studies, a growing number of scholars have begun to oppose this claim, suggesting that melatonin may indirectly affect ROR activity via intermediate steps rather than directly binding to ROR. Therefore, whether ROR is a nuclear receptor for melatonin remains controversial (Table 2).

A study by Slominski et al. noted that melatonin and its metabolites, including 6OH-melatonin, AFMK (N1-acetyl-N2-formyl-5-methoxykynuramine), 5-methoxytriptophol,
and 5-methoxytriptamine, exhibited no significant impact on the transcriptional activity of RORα and RORγ (p > 0.05) [17]. Molecular modelling further revealed that melatonin and its metabolites were not high-affinity ROR ligands [17].

Furthermore, some believe that melatonin cannot function as a ligand for ROR due to the significant differences in structure between melatonin and its metabolites and the identified ROR ligands (lipids, comprising cholesterol, steroids, and retinoids) [122]. However, it is worth noting that the argument of structural similarity between putative ligands should be made with caution, as the ligand-binding pockets of nuclear receptors are often highly plastic, allowing them to accommodate ligands with radically distinct structures. For instance, RXR is shown to bind tributyltin, retinoids, and fatty acids [1].

Although the direct binding between melatonin and ROR has been challenged, melatonin has been found to function via ROR or to modulates the transcriptional activity of ROR in a number of studies. To elaborate on this further, it has been proposed that melatonin indirectly regulates the transcriptional activity of ROR or modulates ROR expression and its downstream signalling pathways through certain steps. Recently, emerging studies have provided evidence for these proposals.

The first possibility is that melatonin directly binds to membrane receptors (MT1 or MT2), other receptors, or regulatory proteins (undefined), and further modulates the transcription or translation of ROR, contributing to alterations in ROR transcriptional activity. Some studies have validated this hypothesis. In MCF-7 breast cancer cells, both MT1 and RORα mediate the anti-tumour effects of melatonin. However, MT1 inhibitors reverse the melatonin-induced activation of ROR, suggesting that melatonin indirectly regulates RORα by the mediation of the MT1 receptor [15]. In addition, melatonin also acts against myocardial ischemia-reperfusion by directly binding to MT2 and subsequently regulating RORα signalling [16].

The second possibility is that melatonin acts via the melatonin-Sirt1-circadian oscillator pathway. Melatonin upregulates SIRT1 in multiple ways [123–125]. Furthermore, SIRT1, an NAD+-dependent protein deacetylase, moderates central and peripheral circadian oscillators [126]. The proposed mechanism postulates that SIRT1 deacetylates PPARγ coactivator-1α (PGC-1α) and the deacetylated form of PGC-1α binds to ROR, contributing to the transcriptional activation of ROR target genes. This implies that melatonin may moderate the transcriptional activity of ROR via downstream SIRT1 signalling [6].

A third explanation is that melatonin and its metabolites can alter cellular redox statuses (NADH/NAD and NADP/NADP ratios), which influence oxidative phosphorylation and the pentose phosphate pathways. This leads to adjustments in the circadian oscillator system, including the expression and the transcriptional activity of ROR. Another mechanism could be that melatonin induces alterations in mitochondrial activity, which in turn affects ROR activity [127].

Finally, it has been suggested that melatonin signalling directly regulates the transcriptional activity of the REV-ERB. Since REV-ERB competes with ROR for binding to RORE, REV-ERB regulation is equivalent to the reverse modulation on ROR transcriptional activity. Recent studies have provided evidence for this proposal [43].

Since Wiesenberg et al. reported that melatonin and the synthetic ligand CGP52608 similarly bound to and activated RORαs, several studies have suggested that CGP52608 could mimic melatonin binding to the nuclear receptor ROR. However, this claim rests on the hypothesis that melatonin binds to ROR. If melatonin indirectly modulates ROR activity, then the melatonin-mimicking claims of CGP52608 are bound to collapse. Furthermore, melatonin acts differently from CGP52608. For instance, both melatonin and CGP52608 inhibit the growth of MCF-7 breast cancer cells, but CGP-52608 inhibits MCF-7 cell growth with a very different dose-response than melatonin [15]. Furthermore, melatonin boosts the proliferation of rat epididymal epithelial cells, while CGP52608 acts as an inhibitor [128]. Therefore, the use of CGP52608 as a mimic of melatonin for ROR binding assays should be discarded.
5. Perspectives

No consensus has been reached on whether ROR is a nuclear receptor of melatonin. Both the expression pattern and functions of ROR are linked to melatonin to some degree. Some studies have suggested that melatonin works akin to ROR ligands, regulating the transcriptional activity of ROR [12–14]. Co-localization and co-immunoprecipitation of melatonin and ROR have been reported, illustrating their interaction [14]. Nevertheless, another study claiming the binding and activation of RORβ by melatonin is unreproducible [10]. Furthermore, crystallographic research and molecular modelling have implied that melatonin and its metabolites are not likely to be ROR ligands [7]. Moreover, the existence of certain intermediate steps that allow melatonin to indirectly modulate ROR expression and function has been confirmed [15]. Other potential transitional steps and pathways have also been proposed.

Thus, further research is warranted to shed more light on this issue. First, there are few published studies that provide direct evidence for the binding between melatonin and ROR (such as co-immunoprecipitation assays). Replications conducted by different groups are needed to obtain more reliable and convincing results. Second, it is proposed that melatonin may be a mid-affinity ligand for ROR. However, high-affinity ligands for ROR, such as cholesterol and steroids, are commonly present in cell culture media of experimental systems. The impact of other ligands needs to be excluded when testing the binding of melatonin to ROR. Finally, some studies have concluded that melatonin performs certain functions by binding to the ROR, based solely on the exclusion of membrane receptor mediation. However, such conclusions are not rigorous, owing to the possible existence of other unidentified receptors or regulatory proteins for melatonin. Therefore, based on the available scientific evidence, we conclude that the mechanisms underlying the effects exerted by melatonin need to be explored further until reproducible and reliable results are made available. We believe that the reports on ROR and melatonin should be more cautious and conservative in their presentation till the final conclusions are drawn.

Author Contributions: Conceptualization, H.M., W.F., H.H., and F.H.; methodology, H.M.; validation, H.M.; formal analysis, H.M.; investigation, H.M.; resources, H.M.; writing—original draft preparation, H.M.; writing—review and editing, J.K., H.H., and F.H.; visualization, H.M.; supervision, J.K., H.H., and F.H.; project administration, W.F., H.H., and F.H.; funding acquisition, H.H., W.F., and F.H. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by the National Natural Science Foundation of China (81870737); the Natural Science Foundation of Guangdong Province (2021A1515011779); National Natural Science Foundation of China (81771098); the National Natural Science Foundation of China (81371107); the Guangdong Financial Fund for High-Caliber Hospital Construction (174-2018-XMZC-0001-03-0125/D-02).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: We appreciate the support from the Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, and the Guangdong Provincial Key Laboratory of Stomatology.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Evans, R.M.; Mangelsdorf, D.J. Nuclear Receptors, RXR, and the Big Bang. Cell 2014, 157, 255–266. [CrossRef] [PubMed]
2. Evans, R.M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240, 889–895. [CrossRef] [PubMed]
3. Giguere, V.; Tini, M.; Flock, G.; Ong, E.; Evans, R.M.; Ottulakowski, G. Isoform-specific amino-terminal domains dictate DNA-binding properties of ROR alpha, a novel family of orphan hormone nuclear receptors. Genes Dev. 1994, 8, 538–553. [CrossRef] [PubMed]
4. Ladurner, A.; Schwarz, P.F.; Dirsch, V.M. Natural products as modulators of retinoic acid receptor-related orphan receptors (RORs). Nat. Prod. Rep. 2021. [CrossRef]

5. Ferlazzo, N.; Andolina, G.; Cannata, A.; Costanzo, M.G.; Rizzo, V.; Currò, M.; Ientile, R.; Caccamo, D. Is Melatonin the Cornucopia of the 21st Century? Antioxidants 2020, 9, 1088. [CrossRef] [PubMed]

6. Liu, L.; Labani, N.; Cecon, E.; Jockers, R. Melatonin Target Proteins: Too Many or Not Enough? Front. Endocrinol. 2019, 10, 791. [CrossRef] [PubMed]

7. Slominski, R.M.; Reiter, R.J.; Schlabritz-Loutsevitch, N.; Ostrom, R.S.; Slominski, A.T. Melatonin membrane receptors in peripheral tissues: Distribution and functions. Mol. Cell Endocrinol. 2012, 351, 152–166. [CrossRef] [PubMed]

8. Acuña-Castroviejo, D.; Reiter, R.J.; Menéndez-Pelaez, A.; Pablos, M.I.; Burgos, A. Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver. J. Pineal Res. 1994, 16, 100–112. [CrossRef]

9. Rafii-El-Idrissi, M.; Calvo, J.R.; Harmouch, A.; García-Mauriño, S.; Guerrero, J.M. Specific binding of melatonin by purified cell nuclei from spleen and thymus of the rat. J. Neuroimmunol. 1998, 86, 190–197. [CrossRef]

10. Becker-Andr, M.; Wiesenberg, I.; Schaeren-Wiemers, N.; Andr, M.; Missbach, M.; Saurat, J.H.; Carlberg, C. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J. Biol. Chem. 1999, 269, 28531–28534. [CrossRef]

11. Wiesenberg, I.; Missbach, M.; Kahlen, J.P.; Schräder, M.; Carlberg, C. Transcriptional activation of the nuclear receptor RZR alpha by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acids Res. 1995, 23, 327–333. [CrossRef]

12. Zhao, Y.; Xu, L.; Ding, S.; Lin, N.; Ji, Q.; Gao, L.; Su, Y.; He, B.; Pu, J. Novel protective role of the circadian nuclear receptor retinoic acid-related orphan receptor-α in diabetic cardiomyopathy. J. Pineal Res. 2017, 62. [CrossRef]

13. Kim, E.-J.; Yoo, Y.-G.; Yang, W.-K.; Lim, Y.-S.; Na, T.-Y.; Lee, I.-K.; Lee, M.-O. Transcriptional Activation of HIF-1 by RORα and its Role in Hypoxia Signaling. Arterioscler. Throm. Vasc. Biol. 2008, 28, 1796–1802. [CrossRef]

14. Lardone, P.J.; Guerrero, J.M.; Fernández-Santos, J.M.; Rubio, A.; Martín-Lacave, I.; Carrillo-Vico, A. Melatonin synthesized by T lymphocytes as a ligand of the retinoic acid-related orphan receptor. J. Pineal Res. 2011, 51, 454–462. [CrossRef]

15. Ram, P.T.; Dai, J.; Yuan, L.; Dong, C.; Kiefer, T.L.; Lai, L.; Hill, S.M. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett. 2002, 179, 141–150. [CrossRef]

16. Han, D.; Wang, Y.; Chen, J.; Zhang, J.; Yu, P.; Zhang, R.; Li, S.; Tao, B.; Wang, Y.; Qiu, Y.; et al. Activation of melatonin receptor 2 but not melatonin receptor 1 mediates melatonin-conferred cardioprotection against myocardial ischemia/reperfusion injury. J. Pineal Res. 2019, 67, e12571. [CrossRef]

17. Slominski, A.T.; Kim, T.K.; Takeda, Y.; Janjetovic, Z.; Brozyna, A.A.; Skobowiat, C.; Wang, J.; Postlethwaita, A.; Li, W.; Tuckey, R.C.; et al. ROXs and RORγ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D. FASEB J. 2014, 28, 2775–2789. [CrossRef]

18. Menendez-Pelaez, A.; Reiter, R.J. Distribution of melatonin in mammalian tissues: The relative importance of nuclear versus cytosolic localization. J. Pineal Res. 1993, 15, 59–69. [CrossRef]

19. Acuña-Castroviejo, D.; Pablos, M.I.; Menéndez-Pelaez, A.; Reiter, R.J. Melatonin receptors in purified cell nuclei of liver. Res. Commun. Chem. Pathol. Pharmacol. 1993, 82, 253–256.

20. Solt, L.A.; Griffin, P.R.; Burris, T.P. Ligand regulation of retinoic acid receptor-related orphan receptors: Implications for development of novel therapeutics. Curr. Opin. Lipidol. 2010, 21, 204–211. [CrossRef]

21. Liu, H.; Aramaki, M.; Fu, Y.; Forrest, D. Chapter Eight—Retinoid-Related Orphan Receptor β and Transcriptional Control of Neuronal Differentiation. In Current Topics in Developmental Biology; Forrest, D., Tsai, S., Eds.; Academic Press: Cambridge, MA, 2017; Volume 125, pp. 227–255.

22. Feng, S.; Xu, S.; Wen, Z.; Zhu, Y. Retinoic acid-related orphan receptor RORB, circadian rhythm abnormalities and tumorigenesis (Review). Int. J. Mol. Med. 2015, 35, 1493–1500. [CrossRef] [PubMed]

23. Fu, Y.; Liu, H.; Ng, L.; Kim, J-W.; Hao, H.; Swaroop, A.; Forrest, D. Feedback Induction of a Photoreceptor-specific Isoform of Retinoid-related Orphan Nuclear Receptor β by the Rod Transcription Factor NRL. J. Biol. Chem. 2014, 289, 32469–32480. [CrossRef] [PubMed]

24. Jetten, A.M.; Cook, D.N. (Inverse) Agonists of Retinoic Acid-Related Orphan Receptor γ: Regulation of Immune Responses, Inflammation, and Autoimmune Disease. Annu. Rev. Pharmacol. Toxicol. 2020, 60, 371–390. [CrossRef] [PubMed]

25. Montaldo, E.; Juelke, K.; Romagnani, C. Group 3 innate lymphoid cells (ILC3s): Origin, differentiation, and plasticity in humans and mice. Eur. J. Immunol. 2015, 45, 2171–2182. [CrossRef]

26. Stadhouders, R.; Lubberts, E.; Hendriks, R.W. A cellular and molecular view of T helper 17 cell plasticity in autoimmunity. J. Autoimmun. 2018, 87, 1–15. [CrossRef]

27. Ding, S.; Lin, N.; Sheng, X.; Zhao, Y.; Su, Y.; Xu, L.; Tong, R.; Yan, Y.; Fu, Y.; He, J.; et al. Melatonin stabilizes rupture-prone vulnerable plaques via regulating macrophage polarization in a nuclear circadian receptor RORα-dependent manner. J. Pineal Res. 2019, 67, e12581. [CrossRef]

28. Farez, M.F.; Calandre, I.L.; Correale, J.; Quintana, F.J. Anti-inflammatory effects of melatonin in multiple sclerosis. Bioessays 2016, 38, 1016–1026. [CrossRef]

29. Huang, H.; Liu, X.; Chen, D.; Lu, Y.; Li, J.; Du, F.; Zhang, C.; Lu, L. Melatonin prevents endothelial dysfunction in SLE by activating the nuclear receptor retinoic acid-related orphan receptor-α. Int. Immunopharmacol. 2020, 83, 106365. [CrossRef]
30. García, J.A.; Volt, H.; Venegas, C.; Doerrier, C.; Escames, G.; López, L.C.; Acuña-Castroviejo, D. Disruption of the NF-κB/NLRP3 connection by melatonin requires retinoid-related orphan receptor-α and blocks the septic response in mice. *FASEB J.* 2015, 29, 3863–3875. [CrossRef]

31. Yasui, H.; Matsuzaki, Y.; Komno, A.; Hirai, H. Global Knockdown of Retinoid-related Orphan Receptor α in Mature Purkinje Cells Reveals Aberrant Cerebellar Phenotypes of Spinocerebellar Ataxia. *Neuroscience* 2020. [CrossRef]

32. Clark, E.A.; Rutlin, M.; Capano, L.; Aviles, S.; Saadon, J.R.; Taneja, P.; Zhang, Q.; Bullis, J.B.; Lauer, T.; Myers, E.; et al. Cortical RORα is required for layer 4 transcriptional identity and barrel integrity. *eLife* 2020, 9, e5270. [CrossRef]

33. Boudry-Labis, E.; Demeere, B.; Le Caigncy, C.; Isidor, B.; Mathieu-Dramard, M.; Plessis, G.; George, A.M.; Taylor, J.; Aftimos, S; Wiemer-Kruel, A.; et al. A novel microdeletion syndrome at 9q21.13 characterised by mental retardation, speech delay, epilepsy and characteristic facial features. *Eur. J. Med. Genet.* 2013, 56, 163–170. [CrossRef]

34. Rudolf, G.; Lesca, G.; Mehrjouy, M.M.; Labalme, A.; Salmi, M.; Bache, I.; Bruneau, N.; Fluss, J.; de Bellescize, J.; et al. Loss of function of the retinoid-related nuclear receptor (RORB) gene and epilepsy. *Eur. J. Hum. Genet.* 2016, 24, 1761–1770. [CrossRef]

35. Li, Z.; Zhao, J.; Liu, H.; Wang, J.; Lu, W. Melatonin inhibits apoptosis in mouse Leydig cells via the retinoic acid-related orphan receptor α/p53 pathway. *Life Sci.* 2020, 246, 117431. [CrossRef]

36. Zang, M.; Zhao, Y.; Gao, L.; Zhong, F.; Qin, Z.; Tong, R.; Ai, L.; Petersen, L.; Yan, Y.; Gao, Y.; et al. The circadian nuclear receptor RORα regulates cerebral ischemia-reperfusion injury and mediates the neuroprotective effects of melatonin. *BBA Mol. Basis Dis.* 2020, 1866, 168590. [CrossRef]

37. Xu, L.; Su, Y.; Zhao, Y.; Sheng, X.; Tong, R.; Ying, X.; Gao, L.; Ji, Q.; Gao, Y.; Yan, Y.; et al. Melatonin differentially regulates pathological and physiological cardiac hypertrophy: Crucial role of circadian nuclear receptor RORα signaling. *J. Pineal Res.* 2019, 67, e12579. [CrossRef]

38. He, B.; Zhao, Y.; Xu, L.; Gao, L.; Su, Y.; Lin, N.; Pu, J. The nuclear melatonin receptor RORα is a novel endogenous defender against myocardial ischemia/reperfusion injury. *J. Pineal Res.* 2016, 60, 313–326. [CrossRef]

39. Wang, R.X.; Liu, H.; Xu, L.; Zhang, H.; Zhou, R.X. Melatonin downregulates nuclear receptor RZR/RORγ expression causing growth-inhibitory and anti-angiogenesis activity in human gastric cancer cells in vitro and in vivo. *OncoL. Lett.* 2016, 12, 897–903. [CrossRef]

40. Meissburger, B.; Ukopec, J.; Roeder, E.; Beaton, N.; Geiger, M.; Teupser, D.; Civan, B.; Langhans, W.; Nawroth, P.P.; Gasperikova, D.; et al. Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gamma. *EMBO Mol. Med.* 2011, 3, 637–651. [CrossRef]

41. Deng, S.L.; Zhang, Y.; Yu, K.; Wang, X.X.; Chen, S.R.; Han, D.P.; Cheng, C.Y.; Lian, Z.X.; Liu, Y.X. Melatonin up-regulates the expression of the GATA-4 transcription factor and increases testosterone secretion from Leydig cells through RORα signaling in an in vitro goat spermatogonial stem cell differentiation culture system. *Onco target* 2017, 8, 110592–110605. [CrossRef]

42. Hong, Y.; Won, J.; Lee, Y.; Lee, S.; Park, K.; Chang, K.T.; Hong, Y. Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells. *J. Pineal Res.* 2014, 56, 264–274. [CrossRef] [PubMed]

43. Sánchez, D.I.; González-Fernández, B.; Crespo, I.; San-Miguel, B.; Álvarez, M.; González-Gallego, J.; Tuñón, M.J. Melatonin modulates dysregulated circadian clocks in mice with diethylnitrosamine-induced hepatocellular carcinoma. *J. Pineal Res.* 2018, 65, e12506. [CrossRef] [PubMed]

44. Shajari, S.; Laliena, A.; Heegsma, J.; Tuñón, M.J.; Moshage, H.; Faber, K.N. Melatonin suppresses activation of hepatic stellate cells through RORα-mediated inhibition of 5-lipoxygenase. *J. Pineal Res.* 2015, 59, 391–401. [CrossRef] [PubMed]

45. Fischer, T.W.; Slominski, A.; Tobin, D.J.; Paus, R. Melatonin and the hair follicle. *J. Pineal Res.* 2008, 44, 1–15. [CrossRef]

46. González-Fernández, B.; Crespo, I.; San-Miguel, B.; de Urbina, J.O.; González-Gallego, J.; Tuñón, M.J. Melatonin Attenuates Dysregulation of the Circadian Clock Pathway in Mice With CCl4(4)-Induced Fibrosis and Human Hepatic Stellate Cells. *Front. Pharmacol.* 2018, 9, 556. [CrossRef]

47. Lin, J.J.; Lin, Y.; Zhao, T.Z.; Zhang, C.K.; Zhang, T.; Chen, X.L.; Ding, J.Q.; Chang, T.; Zhang, Z.; Sun, C.; et al. Melatonin Suppresses Neuropathic Pain via MT2-Derived and -Independent Pathways in Dorsal Root Ganglia Neurons of Mice. *Theranostics* 2017, 7, 2015–2032. [CrossRef]

48. Min, H.Y.; Son, H.E.; Jang, W.G. Estradiol-induced RORα expression positively regulates osteoblast differentiation. *Steroids* 2019, 149, 108412. [CrossRef]

49. Fitzsimmons, R.L.; Lau, P.; Muscat, G.E.O. Retinoid-related orphan receptor alpha and the regulation of lipid homeostasis. *J. Steroid. Biochem.* 2012, 130, 159–168. [CrossRef]

50. Masana, M.I.; Sumaya, I.C.; Becker-Andre, M.; Dubocovich, M.L. Behavioral characterization and modulation of circadian rhythms by light and melatonin in C3H/HeN mice homozygous for the RORβ knockout. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2007, 292, R2357–R2367. [CrossRef]

51. Liu, H.; Kim, S.Y.; Fu, Y.; Wu, X.; Ng, L.; Swaroop, A.; Forrest, D. An isoform of retinoid-related orphan receptor β directs differentiation of retinal amacrine and horizontal interneurons. *Nat. Commun.* 2013, 4, 1813. [CrossRef]

52. Farr, J.N.; Wei, V.; Nicks, K.M.; Fraser, D.G.; Negley, B.A.; Onken, J.L.; Thicke, B.S.; Ruan, M.; Liu, H.; Forrest, D.; et al. Osteoprotection Through the Deletion of the Transcription Factor Rorβ in Mice. *J. Bone Miner. Res.* 2018, 33, 720–731. [CrossRef]
53. Aquino-Martinez, R.; Farr, J.N.; Weivoda, M.M.; Negley, B.A.; Onken, J.L.; Thicke, B.S.; Fulcher, M.M.; Fraser, D.G.; van Wijnen, A.J.; Khosla, S.; et al. miR-219a-5p Regulates Rorγ During Osteoblast Differentiation and in Age-related Bone Loss. J. Bone Miner. Res. 2019, 34, 135–144. [CrossRef]

54. Xu, L.; Zhang, L.; Wang, Z.; Li, C.; Li, S.; Li, L.; Fan, Q.; Zheng, L. Melatonin Suppresses Estrogen Deficiency-Induced Osteoporosis and Promotes Osteoblastogenesis by Inactivating the NLRP3 Inflammasome. Calcif. Tissue Int. 2018, 103, 400–410. [CrossRef]

55. Sun, Z.; Unutmaz, D.; Zou, Y.R.; Sunshine, M.J.; Pierani, A.; Brenner-Morton, S.; Mebius, R.E.; Litman, D.R. Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science 2000, 288, 2369–2373. [CrossRef]

56. Jetten, A.M.; Takeda, Y.; Slominski, A.; Kang, H.S. Retinoic acid-related Orphan Receptor γ (ROγR): Connecting sterol metabolism to the regulation of the immune system and autoimmune diseases. Curr. Opin. Toxicol. 2018, 8, 66–80. [CrossRef]

57. Zhang, S.; Takaku, M.; Zou, L.; Gu, A.-d.; Chou, W.-C.; Zhang, G.; Wu, B.; Kong, Q.; Thomas, S.Y.; Serody, J.S.; et al. Reversing SKI-SMAD4-mediated suppression is essential for T(H)17 cell differentiation. Nature 2017, 551, 105–109. [CrossRef]

58. Kasal, D.N.; Bendelac, A. Multi-transcription factor reporter mice delineate early precursors to the ILC and LTi lineages. J. Exp. Med. 2021, 218. [CrossRef]

59. Capone, A.; Volpe, E. Transcriptional Regulators of T Helper 17 Cell Differentiation in Health and Autoimmune Diseases. Front. Immunol. 2020, 11, 348. [CrossRef]

60. Isono, F.; Fujita-Sato, S.; Ito, S. Inhibiting RORγt/Th17 axis for autoimmune disorders. Drug Discov. Today 2014, 19, 1205–1211. [CrossRef]

61. Zhang, K.; Li, H.; Xin, Z.; Li, Y.; Wang, X.; Hu, Y.; Liu, H.; Cai, D. Time-restricted feeding downregulates cholesterol biosynthesis in porcine liver organoids. J. Anim. Sci. Biotechnol. 2021, 106. [CrossRef]

62. Fan, J.; Lv, Z.; Yang, G.; Liao, T.T.; Xu, J.; Wu, D.-h.; Xu, Y. ROR nuclear receptors: Structures, related diseases, and drug discovery. Acta Pharmacol. Sin. 2015, 36, 71–87. [CrossRef]

63. Zhang, Y.; Luo, X.-y.; Wu, D.-h.; Xu, Y. ROR nuclear receptors: Structures, related diseases, and drug discovery. Acta Pharmacol. Sin. 2015, 36, 71–87. [CrossRef]

64. McMullan, C.J.; Curhan, G.C.; Forman, J.P. Association of nocturnal melatonin secretion with insulin resistance in nondiabetic young women. Am. J. Epidemiol. 2013, 178, 231–238. [CrossRef]

65. Zhang, K.; Li, H.; Xin, Z.; Li, Y.; Wang, X.; Hu, Y.; Liu, H.; Cai, D. Time-restricted feeding downregulates cholesterol biosynthesis program via RORγ-mediated chromatin modification in porcine liver organoids. J. Anim. Sci. Biotechnol. 2020, 11, 106. [CrossRef]

66. Sun, Z.; Xu, Y. Nuclear Receptor Coactivators (NCOAs) and Corepressors (NCORs) in the Brain. Endocrinology 2020, 161. [CrossRef]

67. Zhang, K.; Li, H.; Xin, Z.; Li, Y.; Wang, X.; Hu, Y.; Liu, H.; Cai, D. Time-restricted feeding downregulates cholesterol biosynthesis program via RORγ-mediated chromatin modification in porcine liver organoids. J. Anim. Sci. Biotechnol. 2020, 11, 106. [CrossRef]

68. Fan, J.; Lv, Z.; Yang, G.; Liao, T.T.; Xu, J.; Wu, F.; Huang, Q.; Guo, M.; Hu, G.; Zhou, M.; et al. Retinoic Acid Receptor-Related Orphan Receptors: Critical Roles in Tumorigenesis. Front. Immunol. 2019, 8, 1187. [CrossRef]

69. Zhang, K.; Li, H.; Xin, Z.; Li, Y.; Wang, X.; Hu, Y.; Liu, H.; Cai, D. Time-restricted feeding downregulates cholesterol biosynthesis program via RORγ-mediated chromatin modification in porcine liver organoids. J. Anim. Sci. Biotechnol. 2020, 11, 106. [CrossRef]

70. Gold, D.A.; Baek, S.H.; Schork, N.J.; Rose, D.W.; Larsen, D.D.; Sachs, B.D.; Rosenfeld, M.G.; Hamilton, B.A. RORalpha coordinates reciprocal signaling in cerebellar development through sonic hedgehog and calcium-dependent pathways. Neuron 2003, 40, 1119–1131. [CrossRef]

71. Gooley, J.J. Circadian regulation of lipid metabolism. Proc. Nutr. Soc. 2016, 75, 440–450. [CrossRef]

72. Singh, A.K.; Khare, P.; Obaid, A.; Conlon, K.P.; Basrur, V.; DePinho, R.A.; Venuprasad, K. SUMOylation of ROR-γt inhibits IL-17 expression and inflammation via HDAC2. Nat. Commun. 2018, 9, 4515. [CrossRef]

73. Kathania, M.; Khare, P.; Zeng, M.; Cantarel, B.; Zhang, H.; Ueno, H.; Venuprasad, K. Itch inhibits IL-17-mediated colon inflammation and tumorigenesis by RORγt ubiquitination. Nat. Immunol. 2016, 17, 997–1004. [CrossRef]

74. Zeller, J.; Isaac, A.; Be, C.; Arista, L.; Orain, D.; Kaupmann, K.; Guntermann, C.; Hoegenera, K.; Hintzerm, F. Structural States of RORγT: X-ray Elucidation of Molecular Mechanisms and Binding Interactions for Natural and Synthetic Compounds. ChemMedChem 2017, 12, 1014–1021. [CrossRef]

75. Han, Y.-H.; Shin, K.-O.; Kim, J.-Y.; Khadka, D.B.; Kim, H.-J.; Lee, Y.-M.; Cho, W.-J.; Cha, J.-Y.; Lee, B.-J.; Lee, M.-O. A maresin 1/RORα/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis. J. Clin. Invest. 2019, 129, 1684–1698. [CrossRef]

76. Solt, L.A.; Kumar, N.; Nuhant, P.; Wang, Y.; Lauer, J.L.; Liu, J.; Istrate, M.A.; Kamenecka, T.M.; Roush, W.R.; Vidović, D.; et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 2011, 472, 491–494. [CrossRef]

77. Solt, L.A.; Banerjee, S.; Campbell, S.; Kamenecka, T.M.; Burris, T.P. ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes. Endocrinology 2015, 156, 869–881. [CrossRef]

78. Jakel, H.; Fruchtad-Najb, J.; Fruchtad, J.C. Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosis. Drug News Perspect. 2006, 19, 91–97. [CrossRef]

79. Lee, I.K.; Song, H.; Kim, H.; Kim, I.S.; Tran, N.L.; Kim, S.H.; Oh, S.J.; Lee, J.M. RORα Regulates Cholesterol Metabolism of CD8(+) T Cells for Anticancer Immunity. Cancers 2020, 12, 1733. [CrossRef]
80. Park, J.S.; Moon, S.J.; Lim, M.A.; Byun, J.K.; Hwang, S.H.; Yang, S.; Kim, E.K.; Lee, H.; Kim, S.M.; Lee, J.; et al. Retinoic Acid Receptor-Related Receptor Alpha Ameliorates Autoimmune Arthritis via Inhibiting of Th17 Cells and Osteoclastogenesis. *Front. Immunol.* **2019**, *10*, 2270. [CrossRef]

81. Fujita-Sato, S.; Ito, S.; Isobe, T.; Ohayama, T.; Wakabayashi, K.; Morishita, K.; Ando, O.; Isono, F. Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production. *J. Biol. Chem.* **2011**, *286*, 31409–31417. [CrossRef]

82. Talia, D.M.; Deliyaniti, D.; Agrotis, A.; Wilkinson-Berka, J.L. Inhibition of the Nuclear Receptor RORgamma Suppresses Neovascular Retinopathy: Involvement of Immune-competent Microglia. *Arterioscler. Thromb. Vasc. Biol.* **2016**, *36*, 1186–1196. [CrossRef]

83. Shi, H.; Mao, X.; Zhong, Y.; Liu, Y.; Zhao, X.; Yu, K.; Zhu, R.; Wei, Y.; Zhu, J.; Sun, H.; et al. Digoxin reduces atherosclerosis in apolipoprotein E-deficient mice. *Br. J. Pharmacol.* **2016**, *173*, 1517–1528. [CrossRef]

84. Lee, J.; Baek, S.; Lee, J.; Lee, D.G.; Park, M.K.; Cho, M.L.; Park, S.H.; Kwok, S.K. Digoxin ameliorates autoimmune arthritis via suppression of Th17 differentiation. *Int. Immunopharmacol.* **2015**, *26*, 103–111. [CrossRef]

85. Karas, K.; Salkowska, A.; Sobalska-Kwapis, M.; Walczak-Drzewiecka, A.; Strapagiel, D.; Dastych, J.; Bachorz, R.A.; Ratajewski, M. Digoxin, an Overlooked Agonist of RORgamma. *Front. Pharmacol.* **2018**, *9*, 460. [CrossRef]

86. Xu, T.; Wang, X.; Zhong, B.; Nurieva, R.I.; Ding, S.; Dong, C. Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORgamma t protein. *J. Biol. Chem.* **2011**, *286*, 22707–22710. [CrossRef]

87. Wang, Y.; Kumar, N.; Solt, L.A.; Richardson, T.I.; Helvering, L.M.; Crumbley, C.; Garcia-Ordonez, R.D.; Stayrook, K.R.; Zhang, X.; Novick, S.; et al. Modulation of retinoic acid receptor-related orphan receptor alpha and gamma activity by 7-oxygenated sterol ligands. *J. Biol. Chem.* **2010**, *285*, 5013–5025. [CrossRef]

88. Jin, L.; Martynowski, D.; Zheng, S.; Wada, T.; Xie, W.; Li, Y. Structural basis for hydroxysterol natural products as ligands of orphan nuclear receptor RORgamma. *Mol. Endocrinol.* **2010**, *24*, 923–929. [CrossRef]

89. Kumar, N.; Solt, L.A.; Conkright, J.J.; Wang, Y.; Istrate, M.A.; Busby, S.A.; Garcia-Ordonez, R.D.; Burris, T.P.; Griffin, P.R. The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonyamide] is a novel retinoic acid receptor-related orphan receptor-alpha/gamma inverse agonist. *Mol. Pharmacol.* **2010**, *77*, 228–226. [CrossRef]

90. Dai, J.; Choo, M.K.; Park, J.M.; Fisher, D.E. Topical ROR Inverse Agonists Suppress Inflammation in Mouse Models of Atopic Dermatitis and Acute Irritant Dermatitis. *J. Invest. Dermatol.* **2017**, *137*, 2523–2531. [CrossRef]

91. Cai, J.; Jiao, X.; Fang, Y.; Yu, X.; Ding, X. The orphan nuclear receptor RORalpha is a potential endogenous protector in renal ischemia/reperfusion injury. *FASEB J.* **2019**, *33*, 5704–5715. [CrossRef] [PubMed]

92. Auclair, M.; Roblot, N.; Capel, E.; Foucher, B.; Antoine, B. Pharmacological modulation of RORalpha controls fat browning, adaptive thermogenesis, and body weight in mice. *Am. J. Physiol. Endocrinol. Metab.* **2021**, *320*, E219–E233. [CrossRef] [PubMed]

93. Han, S.; Li, Z.; Han, F.; Chen, C.; Zhou, Y.; Xu, L. MicroRNA-7, synergizes with RORalpha, negatively controls the pathology of brain tissue inflammation. *J. Neuroinflamm.* **2020**, *17*, 28. [CrossRef]

94. Kim, J.Y.; Han, Y.H.; Nam, M.W.; Kim, H.J.; Lee, M.O. RORalpha suppresses interleukin-6-mediated hepatic acute phase response. *Sci. Rep.* **2019**, *9*, 11798. [CrossRef]

95. Lwin, T.; Yang, J.-L.; Ngampramuan, S.; Vivatpinyo, K.; Chancharoen, P.; Veschsansit, N.; Pinyomahakul, J.; Govitrapong, P.; Mukda, S. Melatonin ameliorates methamphetamine-induced cognitive impairments by inhibiting neuroinflammation via suppression of the TLR4/MyD88/NF-kappaB signaling pathway in the mouse hippocampus. *Prog. Neuro Psychoph.* **2020**, *110109*. [CrossRef]
103. Luo, J.; Zhang, Z.; Sun, H.; Song, J.; Chen, X.; Huang, J.; Lin, X.; Zhou, R. Effect of melatonin on T/B cell activation and immune regulation in pinealectomy mice. *Life Sci.* 2020, 242, 117191. [CrossRef]

104. Deng, S.L.; Zhang, B.L.; Reiter, R.J.; Liu, Y.X. Melatonin Ameliorates Inflammation and Oxidative Stress by Suppressing the p38MAPK Signaling Pathway in LPS-Induced Sheep Orbitalis. *Antioxidants* 2020, 9, 1277. [CrossRef]

105. Ma, S.; Zhu, L.; Fan, X.; Luo, T.; Liu, D.; Liang, Z.; Hu, X.; Shi, T.; Tan, W.; Wang, Z. Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3. *Eur. J. Med. Chem.* 2021, 211, 113027. [CrossRef]

106. Wei, J.; Wang, Y.; Qi, X.; Fan, Z.; Wu, Y. Melatonin ameliorates hyperglycaemia-induced renal inflammation by inhibiting the activation of TLR4 and TGF-β1/Smad3 signalling pathway. *Am. J. Transl. Res.* 2020, 12, 1584–1599.

107. Zhen, G.; Liang, W.; Jia, H.; Zheng, X. Melatonin relieves sepsis-induced myocardial injury via regulating JAK2/STAT3 signaling pathway. *Minerva Med.* 2020. [CrossRef]

108. Ali, T.; Hao, Q.; Ullah, N.; Rahman, S.U.; Shah, F.A.; He, K.; Zheng, C.; Li, W.; Murtaza, I.; Li, Y.; et al. Melatonin Act as an Antidepressive via Attenuation of Neuroinflammation by Targeting Sirt1/Nrf2/HO-1 Signaling. *Front. Mol. Neurosci.* 2020, 13, 96. [CrossRef]

109. Wen, Z.; Pan, T.; Yang, S.; Liu, J.; Tao, H.; Zhao, Y.; Xu, D.; Shao, W.; Wu, J.; Liu, X.; et al. Up-regulated NRP2 in colorectal cancer initiating cells modulates the Wnt pathway by targeting RORβ. *Mol. Cancer* 2017, 16, 20. [CrossRef]

110. Chang, H.-C.; Guarente, L. SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. *J. Pineal Res.* 2018, 65, e12507. [CrossRef] [PubMed]

111. Luo, J.; Zhang, Z.; Sun, H.; Song, J.; Chen, X.; Huang, J.; Lin, X.; Zhou, R. Effect of melatonin on T/B cell activation and immune regulation in pinealectomy mice. *Life Sci.* 2020, 242, 117191. [CrossRef]

112. Deng, S.L.; Zhang, B.L.; Reiter, R.J.; Liu, Y.X. Melatonin Ameliorates Inflammation and Oxidative Stress by Suppressing the p38MAPK Signaling Pathway in LPS-Induced Sheep Orbitalis. *Antioxidants* 2020, 9, 1277. [CrossRef]

113. Ma, S.; Zhu, L.; Fan, X.; Luo, T.; Liu, D.; Liang, Z.; Hu, X.; Shi, T.; Tan, W.; Wang, Z. Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3. *Eur. J. Med. Chem.* 2021, 211, 113027. [CrossRef]

114. Wei, J.; Wang, Y.; Qi, X.; Fan, Z.; Wu, Y. Melatonin ameliorates hyperglycaemia-induced renal inflammation by inhibiting the activation of TLR4 and TGF-β1/Smad3 signalling pathway. *Am. J. Transl. Res.* 2020, 12, 1584–1599.

115. Zhen, G.; Liang, W.; Jia, H.; Zheng, X. Melatonin relieves sepsis-induced myocardial injury via regulating JAK2/STAT3 signaling pathway. *Minerva Med.* 2020. [CrossRef]

116. Ali, T.; Hao, Q.; Ullah, N.; Rahman, S.U.; Shah, F.A.; He, K.; Zheng, C.; Li, W.; Murtaza, I.; Li, Y.; et al. Melatonin Act as an Antidepressive via Attenuation of Neuroinflammation by Targeting Sirt1/Nrf2/HO-1 Signaling. *Front. Mol. Neurosci.* 2020, 13, 96. [CrossRef]

117. Lin, Y.W.; Lee, L.M.; Lee, W.J.; Chu, C.Y.; Tan, P.; Yang, Y.C.; Chen, W.Y.; Yang, S.F.; Hsiao, M.; Chien, M.H. Melatonin inhibits CCAAT/enhancer binding protein-α (C/EBPα) transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-κB. *Cancer Cell Int.* 2020, 20, 65, 140–151. [CrossRef]

118. Cutando, A.; Aneiros-Fernández, J.; López-Valverde, A.; Arias-Santiago, S.; Aneiros-Cachaza, J.; Reiter, R.J. A new perspective in Melatonin’s Effects on Microglial Activation in Hypoxia: In Vitro and In Vivo Evidence. *J. Pineal Res.* 2019, 79, 26. [CrossRef]

119. Chen, H.; Zhang, F.; Yan, T.; Fan, W.; Jiang, L.; He, H.; Huang, F. RORα regulates odontoblastic differentiation and inhibits dental pulp cell invasion by suppressing C-C motif chemokine ligand 24 through inhibition of the c-Jun N-terminal kinase pathway. *J. Pineal Res.* 2020, 67, 20190691. [CrossRef] [PubMed]

120. Liu, J.; Zhou, H.; Fan, W.; Dong, W.; Fu, S.; He, H.; Huang, F. Melatonin influences proliferation and differentiation of rat dental pulp cells in vitro and dentine formation in vivo by altering mitochondrial activity. *J. Pineal Res.* 2013, 54, 170–178. [CrossRef]

121. Kang, J.; Chen, H.; Zhang, F.; Yan, T.; Fan, W.; Jiang, L.; He, H.; Huang, F. RORα regulates odontoblastic differentiation and mediates the pro-odontogenic effect of melatonin on dental papilla cells. *Molecules* 2021, 26, 1098. [CrossRef]

122. Kallen, J.; Schlaeppe, J.-M.; Bitsch, F.; Delhon, I.; Fournier, B. Crystal Structure of the Human RORα Ligand Binding Domain in Complex with Cholesterol Sulfate at 2.2 Å. *J. Biol. Chem.* 2004, 279, 14033–14038. [CrossRef]

123. Ding, M.; Feng, N.; Tang, D.; Feng, J.; Li, Z.; Jia, M.; Liu, Z.; Gu, X.; Wang, Y.; Fu, F.; et al. Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1-PGC1α pathway. *J. Pineal Res.* 2018, 65, e12491. [CrossRef]

124. Hardeland, R. Melatonin and inflammation-Story of a double-edged blade. *J. Pineal Res.* 2018, 65, e12525. [CrossRef]

125. Merlo, S.; Luaces, J.P.; Spampinato, S.F.; Toro-Urrero, N.; Caruso, G.L.; D’Amico, F.; Capani, F.; Sortino, M.A. SIRT1 Mediates Melatonin’s Effects on Microglial Activation in Hypoxia: In Vitro and In Vivo Evidence. *Biomolecules* 2020, 10, 364. [CrossRef]

126. Chang, H.-C.; Guarente, L. SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. *Cell* 2013, 153, 1448–1450. [CrossRef]

127. Reiter, R.J.; Tan, D.X.; Rosales-Corral, S.; Galano, A.; Jou, M.J.; Acuna-Castroviejo, D. Melatonin Mitigates Mitochondrial Meltdown: Interactions with SIRT3. *Int. J. Mol. Sci.* 2018, 19, 2439. [CrossRef] [PubMed]

128. Reiter, R.J.; Tan, D.X.; Rosales-Corral, S.; Galano, A.; Jou, M.J.; Acuna-Castroviejo, D. Melatonin Mitigates Mitochondrial Meltdown: Interactions with SIRT3. *Int. J. Mol. Sci.* 2018, 19, 2439. [CrossRef] [PubMed]

129. Li, L.; Wong, J.T.Y.; Pang, S.F.; Shiu, S.Y.W. Melatonin-induced stimulation of rat corpus epididymal epithelial cell proliferation. *Life Sci.* 1999, 65, 1067–1076. [CrossRef]